Novavax Beats Expectations, Shares Surge

Novavax delivers robust Q1 2026 results, surpassing Wall Street estimates with $139.5M revenue and a narrower EPS loss. The company secures new deals, including a Matrix-M license with Pfizer and material transfer agreements with big pharma players. Shares surge 7% post-announcement, but long-term demand challenges and thin margins persist. Analysts predict a 37.4% revenue drop in the next year, making Novavaxs future hinge on successful partnerships. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/77a5b58f946491bb